Key result
Switching from VKA to DOAC shows no benefit over continued VKA for major composite outcomes.
Why the study?
Whether switching from long-term VKA therapy to a DOAC improves outcomes in frail elderly patients with AF remains uncertain, with limited guideline recommendations.
Does switching from a vitamin K antagonist to a direct oral anticoagulant reduce the composite of stroke/systemic embolism, major bleeding, or all-cause mortality in frail elderly patients with atrial fibrillation?
Meta-Analysis (n=57,099)
Does switching from a vitamin K antagonist to a direct oral anticoagulant reduce the composite of stroke/systemic embolism, major bleeding, or all-cause mortality in frail elderly patients with atrial fibrillation?
Hazard Ratio: 1.18 (95% CI 0.84–1.67)
p-value: p=0.33
In frail elderly patients with atrial fibrillation on established VKA therapy, switching to a DOAC does not significantly reduce thromboembolism, major bleeding, or mortality compared to continuing VKA.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Clinicians should be cautious about automatically switching older, frail patients with AF from VKA therapy to NOAC therapy if the patient is tolerating VKA therapy. For any patient being started on NOAC therapy, careful assessment for potential drug-drug interactions is critical.”
“Switching from a VKA to a DOAC should not be considered without a clear indication in frail older patients with AF”
“The main results were very surprising and unexpected. The FRAIL-AF study was designed as a superiority trial, with the hypothesis that switching from a vitamin K antagonist to a NOAC would lead to less bleeding. However, we saw the opposite, and that's also why the Independent Data and Safety Monitoring Board advised to stop the inclusion of patients.”
No outcome benefit from switching to DOAC in frail elderly AF; supports individualized VKA continuation and dedicated RCTs in this population.
Background: Frailty complicates anticoagulation management in older patients with atrial fibrillation (AF), particularly when long-term vitamin K antagonist (VKA) therapy is already established. Whether switching to a direct oral anticoagulant (DOAC) improves outcomes in this setting remains uncertain, and guideline recommendations are limited. We performed a systematic review and meta-analysis comparing outcomes of VKA-to-DOAC switching versus VKA continuation in frail elderly patients with AF. Methods: MEDLINE, Scopus, and the Cochrane Library were systematically searched from inception through 4 April 2026. Studies enrolling frail elderly patients with AF receiving VKA therapy and directly comparing switching to a DOAC versus continued VKA treatment were eligible. The primary outcome was a composite of stroke/systemic embolism, major bleeding, or all-cause mortality. Adjusted hazard ratios (HRs) were pooled using three-level random-effects models. Results: Four studies (five treatment comparisons) comprising 57,099 patients were included. Overall, switching from VKA to DOAC therapy was not associated with a significant difference in the composite outcome compared with continued VKA treatment (HR 1.18, 95% CI 0.84–1.67). No significant differences were observed for major bleeding (HR 1.13, 95% CI 0.80–1.60), thromboembolism (HR 1.03, 95% CI 0.63–1.68), or all-cause mortality (HR 0.95, 95% CI 0.77–1.16). In analyses restricted to randomized trials, results remained neutral across all outcomes. Conclusion: In frail elderly patients with AF receiving VKA therapy, switching to a DOAC was not associated with significant reductions in thromboembolism, major bleeding, mortality, or the composite outcome compared with continued VKA treatment.
No takes yet. Share an insight, caveat, or question.
Karakasis et al. (2026) conducted a meta-analysis in Atrial fibrillation in frail elderly patients (n=57,099). Direct oral anticoagulants (DOACs) vs. Continued vitamin K antagonist (VKA) therapy was evaluated on Composite of stroke/systemic embolism, major bleeding, or all-cause mortality (HR 1.18, 95% CI 0.84-1.67, p=0.33). Switching from VKA to DOAC therapy was not associated with a significant difference in the composite outcome of stroke/systemic embolism, major bleeding, or all-cause mortality compared with continued VKA treatment (HR 1.18, 95% CI 0.84-1.67, p=0.33).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: